Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biochim Biophys Acta ; 1813(8): 1465-74, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21596068

RESUMEN

Scutellaria baicalensis (SB) and SB-derived polyphenols possess anti-proliferative activities in several cancers, including pancreatic cancer (PaCa). However, the precise molecular mechanisms have not been fully defined. SB extract and SB-derived polyphenols (wogonin, baicalin, and baicalein) were used to determine their anti-proliferative mechanisms. Baicalein significantly inhibited the proliferation of PaCa cell lines in a dose-dependent manner, whereas wogonin and baicalin exhibited a much less robust effect. Treatment with baicalein induced apoptosis with release of cytochrome c from mitochondria, and activation of caspase-3 and -7 and PARP. The general caspase inhibitor zVAD-fmk reversed baicalein-induced apoptosis, indicating a caspase-dependent mechanism. Baicalein decreased expression of Mcl-1, an anti-apoptotic member of the Bcl-2 protein family, presumably through a transcriptional mechanism. Genetic knockdown of Mcl-1 resulted in marked induction of apoptosis. The effect of baicalein on apoptosis was significantly attenuated by Mcl-1 over-expression, suggesting a critical role of Mcl-1 in this process. Our results provide evidence that baicalein induces apoptosis in pancreatic cancer cells through down-regulation of the anti-apoptotic Mcl-1 protein.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Flavanonas/farmacología , Neoplasias Pancreáticas/tratamiento farmacológico , Fitoterapia , Proteínas Proto-Oncogénicas c-bcl-2/genética , Scutellaria baicalensis/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Apoptosis/genética , Apoptosis/fisiología , Caspasas/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Flavanonas/aislamiento & purificación , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Técnicas de Silenciamiento del Gen , Genes bcl-2/efectos de los fármacos , Humanos , Proteína 1 de la Secuencia de Leucemia de Células Mieloides , Proteínas Oncogénicas/metabolismo , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Fenoles/aislamiento & purificación , Fenoles/farmacología , Polifenoles , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-bcl-2/fisiología , Proteínas Virales/metabolismo
2.
Pancreas ; 36(4): 353-62, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-18437081

RESUMEN

OBJECTIVES: Epidemiologic studies suggest that fish oil, rich in n-3 polyunsaturated fatty acids (PUFA), possesses antitumor activity, whereas n-6 PUFAs may stimulate the development of cancers. The aim of this study was to evaluate the effects of n-6 and n-3 PUFAs on the growth of pancreatic cancer. METHODS: The n-6 PUFA arachidonic acid (AA) stimulated the growth of cyclooxygenase (COX) 2 positive human pancreatic cancer (PaCa) cells, which was mediated by COX-2 generated prostaglandin E2 (PGE2) binding to EP2 and EP4 receptors. In contrast, the n-3 PUFA eicosapentaenoic acid decreased the growth of COX-2-positive and COX-2-negative PaCa cells. The COX-2-dependent mechanism of eicosapentaenoic acid was mediated by binding of PGE3 to EP2 and EP4 receptors. Dietary intake of n-3 PUFAs decreased the growth of pancreatic cancers in a xenograft model, which was accompanied by a decrease of PGE2 and an increase of PGE3 in the tumors. CONCLUSIONS: Our studies provide evidence that n-3 PUFAs possess antitumor activities, whereas n-6 PUFAs stimulate pancreatic tumor growth. The opposite effects of n-3 and n-6 PUFAs are mediated by the formation of different prostaglandin species. n-3 PUFAs may prove beneficial as monotherapy or combination therapy with standard chemotherapeutic agents in pancreatic cancer patients.


Asunto(s)
División Celular/efectos de los fármacos , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-6/farmacología , Neoplasias Pancreáticas/patología , Animales , Línea Celular Tumoral , AMP Cíclico/metabolismo , Ciclooxigenasa 2/metabolismo , Humanos , Ratones , Modelos Animales , Neoplasias Pancreáticas/embriología , Reacción en Cadena de la Polimerasa , Prostaglandina-Endoperóxido Sintasas/metabolismo , Prostaglandinas/análisis , ARN Neoplásico/genética , ARN Neoplásico/aislamiento & purificación , Transfección
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA